Solanezumab

Drug Profile

Solanezumab

Alternative Names: Anti-amyloid-beta monoclonal antibody - Eli Lilly; Anti-Aβ monoclonal antibody - Eli Lilly; LY-2062430

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 08 Dec 2016 Additional efficacy and adverse events data from the phase III EXPEDITION3 trial in Alzheimer's disease (Mild dementia) released by Eli Lilly
  • 23 Nov 2016 Eli Lilly announces intention not to pursue regulatory submissions for solanezumab for patients with mild dementia associated with Alzheimer's disease
  • 23 Nov 2016 The phase III EXPEDITION3 trial in Alzheimer's disease (mild dementia) fails to meet primary endpoint and Eli Lilly considers its options
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top